Multiple Myeloma
Conditions
Interventions
Bortezomib (1.3 mg/m2/day) is added to the mobilization regimen on days 1, 8, and 15, in addition to high-dose cyclophosphamide (1.5 g/m2/day) given on day 1 and 2. 400 micrograms/m2/day of filgrastim
Sponsors
Fourth Department of Internal Medicine, Sapporo Medical University, School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Good performance status (0-2). Patients with bad performance status by the osteolytic lesions can be included. 2) Age more than 20 and less than 65 years old. 3) Main Organ function is maintained. 4) Those who are evaluated to be able to survive more than 3 months. 5) In patients receiving the notice, fully briefed for the consent document and other documents given explanation about the contents of the study physician or study investigator, agreed in writing to voluntarily participate in the study by have been obtained.
Exclusion criteria
Exclusion criteria: 1) Patients HIV-HBs-and HCV-positive. 2) Severe hepatic dysfunction, severe renal failure, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled diabetes, uncontrolled hypertension, and uncontrolled infection. 3) Patients with a history of active malignancy. 4) Patients with severe psychiatric disorders. 5) Patients with pregnancy or lactation. 6) Those who are considered as inappropriate to register by attending physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of CD34 cells harvested Toxicities | — |
Countries
Japan
Contacts
Public ContactTsutomu Sato
Sapporo Medical University Hospital Fourth Department of Internal Medicine
Outcome results
None listed